| Symbol | SOPH |
|---|---|
| Name | SOPHIA GENETICS SA |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | LA PIÈCE 12,1180 ROLLE, SAINT-SULPICE, CH-1025, Switzerland |
| Telephone | +41 216941060 |
| Fax | — |
| — | |
| Website | https://www.sophiagenetics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001840706 |
| Description | At SOPHiA GENETICS, we are bringing the power of data and artificial intelligence to healthcare. Our AI platform analyzes multimodal data - including genomics, radiomics, clinical, biological, and digital pathology data - to generate actionable insights for patients with cancer or rare diseases. Today, over 770 healthcare institutions use our cloud-native, consumption-based SaaS platform to bring the power of data-driven medicine to millions of patients across the globe. Beyond the clinical market, our platform is used by BioPharma partners for AI-powered drug discovery, development, and deployment. Additional info from NASDAQ: |
📋 ZHENYU XU (Officer) plans to sell 14K shares of SOPHIA GENETICS SA (at $8.53 each, total $119K) Filed: Aug 27, 2026 | ID: 008777
Read more📋 KATHY L HIBBS (Director) plans to sell 19K shares of SOPHIA GENETICS SA (at $8.45 each, total $158K) Filed: Aug 25, 2026 | ID: 008693
Read moreValente Manuela 🟡 adjusted position in 10.0K shares (1 derivative) of SOPHiA GENETICS SA (SOPH) at $7.94 Transaction Date: Aug 19, 2026 | Filing ID: 000293
Read moreXu Zhenyu 🔴 sold 20.0K shares of SOPHiA GENETICS SA (SOPH) at $8.41 Transaction Date: Aug 19, 2026 | Filing ID: 000292
Read more📋 ZHENYU XU (Officer) plans to sell 6K shares of SOPHIA GENETICS SA (at $8.28 each, total $50K) Filed: Aug 20, 2026 | ID: 008463
Read more📋 ZHENYU XU (Officer) plans to sell 8K shares of SOPHIA GENETICS SA (at $7.62 each, total $61K) Filed: Aug 19, 2026 | ID: 008410
Read moreMenu Philippe 🔴 sold 5.0K shares of SOPHiA GENETICS SA (SOPH) at $7.52 Transaction Date: Aug 12, 2026 | Filing ID: 000283
Read moreVerma Abhimanyu 🔴 sold 5.0K shares of SOPHiA GENETICS SA (SOPH) at $7.60 Transaction Date: Aug 07, 2026 | Filing ID: 000279
Read moreDirector Camblong Jurgi 🔴 sold 28.5K shares of SOPHiA GENETICS SA (SOPH) at $7.61 Transaction Date: Aug 07, 2026 | Filing ID: 000278
Read moreXu Zhenyu 🟡 adjusted position in 20.0K shares (2 derivative) of SOPHiA GENETICS SA (SOPH) at $7.48 Transaction Date: Aug 05, 2026 | Filing ID: 000275
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07663994 | Analytical Validation of Circulating DNA Analysis Methods: Creation of a Contro… | Na | Healthy Volunteers (Cancer) | Completed | 2026-07-16 | 2026-08-17 | ClinicalTrials.gov |
| NCT06525831 | Rein 3D PRINT MECHANICS | Na | Kidney Cancer | Recruiting | 2025-03-07 | 2027-05-07 | ClinicalTrials.gov |
| NCT04994795 | Predictive Multimodal Signatures Associated With Response to Treatment and Prog… | — | Non-small Cell Lung Cancer Metastatic | Active_Not_Recruiting | 2021-08-21 | 2025-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| 1 single blood draw after in the inclusion of the participant in the study (Up to 30 mL). | Other | Approved | Healthy Volunteers (Cancer) | COMPLETED | NCT07663994 |
| 1 single blood draw after in the inclusion of the participant in the study (Up to 30 mL). | Other | Approved | Healthy Volunteers (Cancer) | RECRUITING | NCT07663994 |
| 1 single blood draw after in the inclusion of the participant in the study (Up to 30 mL). | Other | Approved | Healthy Volunteers (Cancer) | RECRUITING | NCT07663994 |
| 1 single blood draw after in the inclusion of the participant in the study (Up to 30 mL). | Other | Approved | Healthy Volunteers (Cancer) | NOT_YET_RECRUITING | NCT07663994 |
| Predictive models (data collection) | Other | Preclinical | Non-small Cell Lung Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT04994795 |
| Ultrasound exam | Other | Approved | Kidney Cancer | RECRUITING | NCT06525831 |
| MR-elastography exam | Other | Approved | Kidney Cancer | RECRUITING | NCT06525831 |
| Predictive models (data collection) | OTHER | Preclinical | Non-small Cell Lung Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT04994795 |